Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer

• Status: Completed
• Trial end date: 2009-11-01

Summary

Bevacizumab is an angiogenesis inhibitor which means it works to stop blood vessel formation in tumors. Without new blood vessels, the growth of a tumor is slowed. Chemotherapy drugs kill cancer cells more directly. This study will evaluate:

• How bevacizumab, given with chemotherapy before surgery, and then bevacizumab given alone after surgery, will affect locally advanced breast tumors

• Side effects from adding bevacizumab to chemotherapy

• Whether adding bevacizumab to chemotherapy for breast cancer will affect the heart

• If receiving bevacizumab will have any effect on how patients recover from surgery

• Side effects of the combinations of drugs used in this study

• Phase: Phase 2

Details

• Lead Sponsor: NSABP Foundation Inc
• Collaborators: Genentech, Inc.; Hoffmann-La Roche; International Drug Development Institute
• Treatments: Bevacizumab; Capecitabine; Cyclophosphamide; Docetaxel; Doxorubicin; Liposomal doxorubicin